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Patients who are treated within clinical trials may have a survival beneﬁt dependent on being a trial participant. A number of
factors may produce such beneﬁcial outcome including more rigorous adherence to a peer reviewed trial protocol,
management by an experienced treatment team, being treated in a specialist centre etc. The current investigation compared
patients treated on and off trial with the same standard arm treatment regimen. The results could then be interpreted without
the confounding factors of differing treatment regimens, treatment teams or treatment hospitals. The results demonstrated
given these circumstances that survival was no different for patients participating in a randomised trial compared with a group
of patients similarly treated who were not eligible for trial entry or who declined randomisation. These results were obtained
by the rigorous adherence to a deﬁned protocol with the invaluable assistance of designated lung cancer staff.
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Chemotherapy is the cornerstone for the management of small cell
lung cancer (SCLC). One of the chemotherapeutic regimens that
has been employed as standard treatment for many years, consists
of cyclophosphamide, doxorubicin and etoposide (CDE). Response
rates are high (70–90%), but as with other chemotherapeutic regi-
mens recurrence frequently occurs. The resulting median and 2-
year survival rates are of the order of 12 months and 20% respec-
tively in patients with good performance status (Souhami and Law,
1990; Thatcher et al, 2000). Attempts to enhance the CDE regimen
by the addition of cisplatin or alternating CDE with vincristine,
carboplatin, ifosphamide combination did not result in any
improvement of survival (Postmus et al, 1996; Urban et al,
1999). However, dose intensiﬁcation by 2-weekly administration
with growth factor support improved the 2-year survival from 8
to 13% compared to the standard 3-weekly CDE schedule, without
additional toxicity (Thatcher et al, 2000). Adjuvant thoracic irra-
diation and prophylactic cranial irradiation have also led to a
modest survival beneﬁt which did not depend on the initial
chemotherapy schedule (Pignon et al, 1992; Arriagada et al, 1995;
Auperin et al, 1999).
However, the outcome of SCLC is not solely related to the anti-
neoplastic therapy. Clinical factors including performance status,
disease stage, serum sodium, liver function tests, lactate dehydro-
genase are important prognostic survival indicators in SCLC. In
order to identify patients with differing prognoses and risk of early
death, these factors have been combined in scoring systems
(Sagman et al, 1991; Thatcher et al, 1995; Lassen et al, 1995).
An intriguing question is whether patients treated within a trial
protocol have an inherently better survival than patients who are
treated ‘off study’. The ﬁnding of statistically signiﬁcant higher
survivals among trial participants than in trial control patients
was highlighted in childhood leukaemia (Stiller and Draper,
1989). Subsequently a beneﬁcial survival effect for participants
has been noted in myeloma, nephroblastoma, non Hodgkin
lymphoma and sarcoma trial patients (Karjalainen and Palva,
1989; Lennox et al, 1979; Wagner et al, 1995; Antman et al, 1985).
The beneﬁt also extended to non-small cell lung cancer where
survival advantage was also apparent for the participants in a trial
for resectable early stage disease (Davis et al, 1985). More recently
small cell lung cancer patients have been reported as having a
better survival when treated within a study protocol rather than
patients treated off protocol (Quoix et al, 1986; Schea et al,
1995). However, these examples suggesting that protocol treatment
is beneﬁcial to the patient refer to situations where the therapy
offered on and off protocol were different which could account
for the survival difference. The Health and Technology Assessment
programme of the NHS reported on some of the issues of rando-
mised clinical trials (RCTs), including the effects of participation
(Edwards et al, 1998). Assessment was made of the trial effects
by plotting the hazard ratios derived from the data set and led
to a view that ‘RCTs tend to be good for you if there is a pre-exist-
ing effective treatment that is included in the trial protocol or if it
turns out that the experimental treatment is more effective.’
However, even without bias, any survival beneﬁt for trial partici-
pants may be due to the effect of a particularly successful
intervention within the trial or ipso facto being a part of the trial
itself (Edwards et al, 1998). Nevertheless the comparison of trial
results with those ‘off trial’ but using the same treatment protocol
does not seem to have been addressed. To try and dissect the issue
further we compared the demographics, treatment characteristics
and survival data of patients with SCLC who were treated on
and off trial but with an identical chemotherapy regimen, the same
treatment guidelines, similar patient characteristics and by one
treatment team.
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The data of patients with SCLC who were treated with CDE
chemotherapy at the Christie Hospital between 1 January 1994
and 1 March 1998 were reviewed retrospectively. During this peri-
od patients were recruited into two phase III randomised clinical
trials which investigated the use of CDE chemotherapy as the stan-
dard treatment arm. One trial has been published (Thatcher et al,
2000) and the other comparing VICE (vincristine, ifosfamide,
carboplatin and etoposide) against a standard regimen which
included CDE has completed recruitment but not yet published.
The inclusion criteria for both trials were similar, i.e. previously
untreated patients with a good prognostic score, adequate liver,
renal function and blood counts (Thatcher et al, 2000). Patients
could have extensive stage disease providing the other prognostic
factors which included biochemical indices and performance status
were not adverse (Cerny et al, 1987). All eligible patients were
invited to participate in one of the two clinical trials. If this for
any reason was not possible due to patients declining, logistics
etc. the off study chemotherapy that was offered during this time
was the CDE schedule. Both on and off trial, the standard regimen
consisted of 40 mg m
72 doxorubicin, 1 g m
72 cyclophosphamide
and 120 mg m
72 etoposide i.v. on day 1 and 240 mg m
72 on day
2 and 3 was given orally. The cycles were repeated every 3 weeks
with a maximum of six cycles or until tumour progression or
severe side effects prohibited therapy.
The next cycle of chemotherapy was only given if the total WBC
was 53000 ml, the neutrophils count was 51500 ml and the plate-
let count 5100000 ml. Dose reduction was not recommended and
growth factor support was allowed. An identical policy e.g. interval,
between cycle blood counts was also applied to the off trial
patients. Each patient was assessed pre-treatment, at each atten-
dance for treatment and regularly there after. A full clinical
examination, blood counts, biochemistry, chest X-ray and other
relevant tests were performed. In case of limited stage disease
patients were offered thoracic radiotherapy. Prophylactic cranial
irradiation was offered to limited stage patients with a complete
tumour response.
Patients for the current analysis were identiﬁed from the records
of the hospital pharmacy which contained all patients treated with
the CDE regimen. Furthermore a double check was performed by a
search of the hospital treatment records for the same period to
identify all small cell lung cancer patients who received any treat-
ment. The hospital ﬁles of all 106 CDE relevant patients could be
traced out of a total of 798 patients with small cell lung cancer
referred to the hospital. The other patients were either on trials
using different regimens or off trial treated with a ‘non-CDE’ regi-
men. The medical records were then screened for the demographics
of the patients, the prognostic factors at the time of diagnosis, the
number of chemotherapy cycles given and the treatment delay
between the chemotherapy cycles, adjuvant radiotherapy and the
survival.
Statistical analysis
Overall survival curves were produced using the Kaplan–Meier
method, and were compared using the log-rank test. The patient
characteristics and response rates were assessed using Person’s w
2
test and Fisher’s Exact test.
RESULTS
One hundred and six SCLC patients were treated with CDE
chemotherapy in the Christie Hospital in the period 1 January
1994 until 1 March 1998. Sixty patients were treated within one
of the two randomised trials and 46 patients were treated off trial.
The characteristics of both patient groups are given in Table 1.
Patients treated on and off trial did not differ signiﬁcantly in their
demographic and prognostic factors. Although the patients treated
on trial showed a tendency toward a better performance status, this
was not statistically signiﬁcant.
The treatment given to both patient groups did not differ signiﬁ-
cantly. The number of cycles of chemotherapy given and the delay
between the cycles were comparable. Consolidation radiotherapy of
the thorax and prophylactic cranial irradiation was offered to a
similar percentage of patients (Table 2).
For all patients not treated within the trial protocol, the reasons
were documented and are given in Table 3. Only 12 out of 46
patients declined trial entry (reasons were not requested), four
patients could not be entered for logistic reasons (holidays etc.)
and the other patients were ineligible due to clinical reasons the
main being impaired renal function.
The tumour response rates derived from radiological reports of
both treatment groups are given in Table 4; again no differences
were detected. Furthermore the survival analysis did not reveal
any difference between the patients treated on and off study. The
median survival for all patients was 345 days (11.3 months), with
330 days (10.9 months) for the patients treated off trial and 346
days (11.4 months) for the patients treated on trial. In both patient
groups, two patients were alive without evidence of disease at the
time of analysis and in both groups two patients died of treatment
related complications. Three patients died from a non-tumour
related cause – ischaemic cardiac disease.
DISCUSSION
Analysis of the survival data of the SCLC patients with CDE
chemotherapy did not reveal any difference between the patients’
treated within a trial protocol and those outside the trial. The ﬁnd-
ing is in contrast with reports suggesting that on study treatment is
an independent prognostic factor, correlated with better survival
(Davis et al, 1985; Schea et al, 1995; Quoix et al, 1986; Wagner
et al, 1995). However, in these studies the treatment regimens on
and off trial protocol were different.
Survival may differ considerably between patients on and off
study because of a differing mix of prognostic factors in the patient
groups. Indeed few study protocols in SCLC include patients with
poorer prognostic factors thereby favouring survival of patients
treated within a particular study when compared with a more
general population (White et al, 2001). However, this difference
was not apparent in the current patient population due to consis-
tency in applying a prognostic scoring system to identify patients
for particular treatment regimens, i.e. CDE chemotherapy. The
system allowed patients with either extensive disease or a poor
performance status to be included on trial provided that this was
the only adverse prognostic factor. As a result the trial population
was reﬂected in the off study population that was analysed.
Furthermore, the distribution of males and females between the
two study groups was very similar, minimising the effect of the
possible favourable prognostic factor of female gender (Johnson
et al, 1988). Reports claiming a beneﬁt for the control group trea-
ted within a trial have in the past compared different treatment
regimens given on and off study, which, could account for any
survival difference (Edwards et al, 1998). In the case of identical
on and off trial therapies, survival could be inﬂuenced by the exis-
tence of more explicit on study treatment protocols, more rigid
adherence to treatment schedules and follow-up guidelines (Colette
et al, 1999). In the current investigation patients both on and off
trial received a comparable number of chemotherapy cycles and
had a similar delay in between the cycles. The received dose inten-
sity, and total dose were therefore similar as was the adjuvant
thoracic irradiation and prophylactic cerebral irradiation. The
study was retrospective, but assuming the off trial patients would
do worse, with 106 patients and a 15% 2-year survival there would
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(5), 562–566be a 70% power to detect a 10% difference with a one-tailed test
and a=5%. The relatively high number of patients on trial was
due in part to the simple trial protocol design. The inclusion criter-
ia were applicable to many patients and the management protocols
for handling haematological toxicity and follow up guidelines were
a reﬂection of routine (off study) practice. Studies with laborious
protocols or where the treatment arms are very different, e.g.
chemotherapy or not, or where there are restrictive patient trial
entry criteria tend to have more problems with patient recruitment;
as illustrated by the 73% refusal rate of eligible patients in a multi-
modality NSCLC trial (Spiro et al, 2000). Indeed of all eligible
patients only 25% agreed to be randomised despite the known will-
ingness amongst cancer patients to participate in clinical research
(Slevin et al, 1995). However, other audits, for example of lympho-
ma, achieved higher recruitment rates of 45%. The main reasons
here for ineligibility were medical, no current study being available
and differences of histological opinion (Hancock et al, 1997). With
fewer patients being excluded from study treatment, patient
outcomes are more directly applicable to routine practice (Quoix
et al, 1986). Indeed in our study only 10% of patients who were
eligible declined to be randomised. Nevertheless patient selection,
either by the patient or physician’s choice, is known to inﬂuence
the distribution of differing tumour stages on and off study
(Antman et al, 1985; Quoix et al, 1986). This discrepancy was
not apparent in our audit which involved a written ‘non trial’
protocol and treatment by a single cohesive clinical and specialist
nursing group experienced in the daily running of trials. Tight
organisation of medical care, speciﬁed treatment by protocol, and
treatment at specialist centres is known to be of survival beneﬁt
(Stiller, 1994).
A number of limitations however, should be kept in mind
during interpretation of results of the current study. The design
of the study was retrospective and patient numbers limited.
Nevertheless data on all patients treated with CDE in the given
time period were retrieved and were analysed. It is important to
know the reasons for not including patients into a trial protocol
since this might give insight into the magnitude of selection of
patients (Quoix et al, 1986). In our study a relatively high percen-
tage of patients were included in trials. The other SCLC patients
were treated in our institution during the time period on different
protocols, e.g. those with a better prognostic score were treated in
protocols of intensive chemotherapy. The main reasons for not
treating patients within trial were medical which accounted for
65% of the patients as can be seen from Table 3, a percentage
similar to other SCLC studies (Quoix et al, 1986). We have no
data on non clinical prognostic factors which could be important
such as socio-economic status. Lung cancer patients living in
better socio-economic areas are known to have more favourable
survival compared to patients living in the lower socio-economic
areas of the southeastern part of the Netherlands (Schrijvers et al,
1995). This observation was conﬁrmed by the Cancer and Leukae-
mia Group B, which reported that small cell lung cancer patients
with a lower annual income and lower educational level had a
shorter survival than those with higher income or education
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Table 1 Patient characteristics
Pt. No (%) Pt. No (%)
OFF-Trial ON-Trial
Age (years) Median 65 63
Range 42–82 44–74
Sex Male 27 (59) 34 (57)
Female 19 (41) 26 (43)
Tumour stage Limited 29 (63) 42 (70)
Extensive 16 (35) 18 (30)
Equivocal 1 (2) – –
Site of tumour Left 21 (46) 28 (47)
Right 24 (52) 31 (51)
Bilateral 1 (2) 1 (2)
Respiratory score 0 2 (4) 8 (13)
1 12 (26) 16 (27)
2 15 (33) 12 (20)
3 12 (26) 17 (28)
4 5 (11) 7 (12)
WHO performance 0 – – 5 (8)
1 31 (67) 35 (58)
2 11 (24) 19 (32)
3 4 (9) 1 (2)
4– – – –
Alkaline phosphatase (U/l) Median 91 90
Range 50–1010 40–367
Na
+ (mmol/l) Median 137 138
Range 132–142 122–144
LDH (U/l) Median 511 526
Range 282–1918 289–2627
No signiﬁcant difference P50.13 for any of the parameters for the off and on trial
groups. Respiratory score for breathlessness (Bleehen et al, 1991).
Table 2 Treatment characteristics
Pt. No (%) Pt. No (%)
OFF-Trial ON-Trial
Chemotherapy cycles given 1 4 (90) 4 (7)
2 5 (11) 2 (3)
3 2 (4) 5 (8)
4 10 (22) 7 (12)
5 5 (11) 3 (5)
6 20 (43) 39 (65)
Treatment delay
Number of cycles with delay 34 (16) 54 (18)
Number of patients with delayed treatment 15 (33) 25 (42)
Radiotherapy none 19 (41) 18 (30)
thoracic 21 (46) 31 (51)
PCI – – 1 (2)
both 6 (13) 10 (16)
No signiﬁcant difference P50.16 for any of the parameters for the off and on trial
groups. PCI=prophylactic cranial irradiation.
Table 3 Reasons for not entering randomised trial (off-study patients)
No. of patients
Patient refusal 12
Ineligible poor renal function 11
adverse prognostic score 527
comorbidity 8
previous malignancy 4
Logistic reasons 4
Total 46
Table 4 Response to chemotherapy
Pt. No (%) Pt. No (%)
Response OFF-Trial ON-Trial
Complete 11 (24) 19 (32)
Partial 22 (49) 19 (32)
Stable disease 8 (17) 12 (20)
Progressive disease 5 (11) 7 (12)
Not assessable – – 3 (5)
No signiﬁcant difference P50.51 for any of the parameters for the off and on trial
groups.
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British Journal of Cancer (2002) 87(5), 562–566 ã 2002 Cancer Research UK(Cella et al, 1991). Indeed in the UK the effects of deprivation on
cancer survival have been reported across a variety of adult
cancers, including lung (Sharp, 1999). Large differences in survival
were noted and for the most afﬂuent patients between 5 and 16%
were more likely to be alive after 5 years than the more deprived
patients (Anderson, 1999). Other non-disease related factors –
the experience of the clinician or institution can inﬂuence survival
as in poor prognosis non seminoma patients (Collette et al, 1999).
In this investigation physicians treating patients at institutions
with low accrual (55 patients per annum) may not have felt
comfortable with the demanding protocol and the management
of toxic effects leading to dose attenuation and failure to adhere
to the protocol (Collette et al, 1999; Feuer et al, 1999). Clearly
if the treatment is relatively ineffective in terms of survival
outcome, e.g. palliative radiotherapy in advanced NSCLC, then
there is unlikely to be major impact even when large patient
numbers are treated (Wheeler et al, 1994).
While some studies which use matched patient populations and
multivariate statistical techniques claim that on study treatment
might be an independent prognostic factor, other studies including
ours did not conﬁrm this view (Edwards et al, 1998). Results of
studies, especially phase III trials can be more directly translated
to daily practice if the on study patient population mirrors that
of the off study population. The current ﬁnding lends conﬁdence
to the concept that strict adherence to a ‘control’ protocol by an
experienced centralised treatment team including dedicated lung
cancer nurses does not result in an inferior effect in terms of survi-
val to that obtained if the same treatment regimen within the trial
context. Such a process does not substitute for the solid evidence
base obtained for randomised clinical trials.
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